This article first appeared on GuruFocus .
Release Date: May 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Tenon Medical Inc ( NASDAQ:TNON ) reported a strong first quarter revenue of $1.4 million, nearly doubling from the previous year.
-
Gross margin improved significantly to 68.5%, up from 44.5% a year ago, marking the highest for any first quarter in the company's history.
-
The company successfully trained 21 physicians across both systems, indicating strong physician engagement.
-
Tenon Medical Inc ( NASDAQ:TNON ) closed a $4.3 million senior convertible note placement, enhancing financial flexibility for future investments.
-
The company's intellectual property portfolio continues to strengthen, with multiple notices of allowance from the U.S. Patent and Trademark Office.
Negative Points
-
Operating expenses increased to $4.2 million, slightly above the $4.0 million from the first quarter of 2025.
-
Despite revenue growth, the company reported a net loss of $3.5 million for the quarter.
-
The company faces challenges in navigating approval and access processes at medical facilities, which can delay product adoption.
-
There is a reliance on continued physician training and engagement to drive product adoption and revenue growth.
-
The company anticipates increased operating expenses due to investments in commercial activities and product launches.
Q & A Highlights
Q: Typically, surgical procedures are down in the first quarter due to co-pay resets. Given this, should we be encouraged by Tenon's strong Q1 numbers relative to Q4? A: Steve Foster, CEO: Absolutely. The dynamics of deductible resets are real, and things tend to settle in Q1. Despite this, we had a strong Q1, which is encouraging and sets a solid foundation for 2026.
Q: How should we think about Q2 relative to Q1, and are there any launch metrics to gauge the progress? A: Steve Foster, CEO: We have a busy 2026 planned with Symmetry Plus moving from Alpha to full launch. Additional components will launch throughout the year, serving as catalysts for growth. We are not waiting for launches to drive growth but expect these new technologies to be significant catalysts.
Q: Is Q1 OpEx a good baseline for the rest of the year, or should we expect changes? A: Kevin Williamson, CFO: Yes, Q1 OpEx is a good baseline. We expect to leverage the P&L and improve profitability by growing revenue and expanding margins faster than OpEx. There will be some investments, but they will be at a lower rate than revenue growth.
Q: Can you discuss the new system expected for alpha release in Q4 2026 and its timeline for commercialization? A: Steve Foster, CEO: The new system will adhere to our core principles of fusion-focused approaches. It will enter alpha in Q4 2026, with a full launch planned for Q1 2027.
Q: How has physician training evolved, and what are the plans to accelerate it? A: Steve Foster, CEO: Training has evolved significantly as we are no longer a single-approach company. We are investing in a training facility in Tampa to accommodate the growing demand and enhance training for physicians and distribution partners.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
